e-Drug3D

2027

MAFODOTIN

DISCONTINUED

INN
BELANTAMAB MAFODOTIN-BLMF
MAFODOTIN

cas 863971-19-1

CLASS

ANTINEOPLASTIC
TREATMENT OF MULTIPLE MYELOMA
ANTIBODY-DRUG CONJUGATE (ADC)
MICROTUBULE INHIBITOR

ROUTE (list)

INTRAVENOUS

ATC code

L01FX15

PK parameters

Tmax 0.78 HOUR
VD 11 LITER

Target

TARGET TUBULIN

DrugCentral

IgG receptor FcRn large subunit p51 UNIPROT P55899 FCGRT

High affinity immunoglobulin gamma Fc receptor I UNIPROT P12314 FCGR1A

Download SDF file

L-Phenylalanine, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(alphaR,betaR,2S)-beta-methoxy-alpha-methyl-2-pyrrolidinepropanoyl-

Formula:
C49H76N6O11

Calculated chemical properties:

MW 924.15
NB_atoms 66
XLogP 2.49
PSA 184.816
NB_HD 2
NB_HA 17
fsp3 0.67
Lipinski(0=no;1=yes) 0

FDA
NDA 761158 (label) INN (BELANTAMAB MAFODOTIN-BLMF) BLENREP (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2020 NEWMOLECULARENTITY OBSOLETE